Viral hemorrhagic fever

This early-stage study tests a new vaccine designed to prevent Sudan virus disease, a severe illness similar to Ebola. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if th…

This early-stage trial is testing an experimental mRNA vaccine called mRNA-1469 to see if it is safe and can trigger an immune response against Ebola-Bundibugyo virus disease. Healthy adults aged 18 to 65 will receive either the vaccine or a placebo. The study focuses on safety a…

This early-stage trial tests a new vaccine (rVSVΔG-MARV-GP) to see if it is safe and triggers an immune response against Marburg virus, a rare but severe disease. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo. The study focuses on side effects a…

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…

This trial tests whether two antiviral drugs, favipiravir and ribavirin, can help clear the virus faster in adults hospitalized with Crimean-Congo hemorrhagic fever (CCHF), a severe tick-borne infection. Participants will receive one of the drugs or optimized standard care, and r…

This study is testing whether the steroid dexamethasone can help people with severe dengue. The researchers will give either dexamethasone or a placebo to 200 infected adults in Thailand. They want to see if the drug lowers the death rate and shortens hospital stays.

This large clinical trial in West Africa is testing several drugs—including favipiravir, ribavirin, dexamethasone, and a new drug called ARN-75039—to find a better treatment for Lassa fever, a viral disease that kills thousands each year. The study will enroll about 1,755 hospita…

This program provides emergency access to REGN-EB3, a combination of three antibodies, for people with confirmed Ebola virus disease. It is available to both adults and children in Ebola-affected regions, including pregnant women. The goal is to offer a potential treatment option…

This study is testing a new rapid diagnostic test for Crimean-Congo hemorrhagic fever (CCHF) that gives results in 20 minutes. Researchers will enroll 492 adults in Turkey with suspected CCHF to see if the test is accurate compared to standard lab methods. The goal is to provide …

This observational study will enroll 190 hospitalized adults with dengue in Bangladesh to see if a 'leaky gut' — where bacteria and toxins escape the intestines into the blood — is linked to severe disease. Researchers will measure gut leakage markers in blood, perform abdominal …

This study creates a registry to collect data on dengue infections in people with congenital bleeding disorders like hemophilia. Dengue can cause serious bleeding, and those with bleeding disorders may face higher risks. The goal is to understand bleeding complications, treatment…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This study creates a global registry to collect information from 200 people with hantavirus infections. Researchers will track how the disease spreads, its symptoms, and what treatments doctors use. No new treatments are tested; the goal is to gather knowledge to improve future c…

This study follows 100 people with confirmed dengue to identify which symptoms and lab results predict hospitalization. It also tracks how often blood transfusions are given and their outcomes. The goal is to improve care for dengue patients, not to test a new treatment.